Mirae Asset Global Investments Co. Ltd. grew its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,116 shares of the biopharmaceutical company’s stock after purchasing an additional 6,296 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.07% of Dynavax Technologies worth $1,218,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. AE Wealth Management LLC bought a new position in shares of Dynavax Technologies in the 3rd quarter worth about $527,000. SG Americas Securities LLC bought a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $1,112,000. State of Alaska Department of Revenue grew its position in shares of Dynavax Technologies by 1.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 79,735 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 1,111 shares during the period. Ziegler Capital Management LLC bought a new stake in shares of Dynavax Technologies in the 3rd quarter valued at $317,000. Finally, Mach 1 Financial Group LLC bought a new position in Dynavax Technologies during the third quarter worth $524,000. Institutional investors and hedge funds own 96.96% of the company’s stock.
Dynavax Technologies Price Performance
DVAX opened at $11.84 on Tuesday. The firm’s fifty day moving average price is $12.31 and its two-hundred day moving average price is $13.26. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -197.30 and a beta of 1.26. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96. Dynavax Technologies Co. has a 1 year low of $10.06 and a 1 year high of $15.15.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Dynavax Technologies
Insider Buying and Selling
In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.98% of the stock is owned by corporate insiders.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
- Five stocks we like better than Dynavax Technologies
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Quiet Period Expirations Explained
- Merger or Not, Albertson’s Companies is a Good Buy
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Cheap Stocks That Shouldn’t Be So
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX – Free Report).
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.